CAR-T

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology

Characterisation of CAR-T cells: Integrating live-cell analysis and high-throughput cytometry

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. This webinar, hosted by DDW and supported by Sartorius, explores the integration of live-cell analysis and high-throughput screening (HTS) by cytometry to enhance the characterisation of CAR-T cells. Key topics… Read More

Webinar date:
Supported by Sartorius
#Webinars

CAR T-cells attacking a cancer cell
#CAR-T #Haematology #Myeloma #Oncology #Phase I trial #Poseida Therapeutics #Roche

Patients show 91% response to allogeneic CAR-T therapy

Investigators saw a 91% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (RRMM) following treatment with allogeneic CAR-T therapy P-BCMA-ALLO1 and lymphodepletion. The interim data from an ongoing Phase I trial in patients who have previously received three or more prior lines of therapy… Read More

#Cancer Research #News

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights vodcast: 24 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week we have seen… Read More

#News

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights podcast: 23 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of developments related to cell therapies, particularly… Read More

#News

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

This week in drug discovery (16-20 September) 

News round-up for 16-20 September by DDW Senior Digital Content Editor Diana Spencer. This week we have seen a number of developments related to cell therapies, particularly CAR-T cell therapies, beyond their traditional use in haematological malignancies. The top stories: Study shows low… Read More

#News

CAR-T therapy
#Autoimmune disease #CAR-T #Cell therapy #Kyverna Therapeutics #Multiple sclerosis

New data support CAR-T therapy in neuroinflammatory diseases

Kyverna Therapeutics has revealed continued positive results for its CAR-T therapy KYV-101 in B cell-driven autoimmune diseases. The clinical trial results and case studies were presented in posters and a company-sponsored symposium at the 40th Congress of the European Committee for Treatment and Research in Multiple… Read More

#Editor's Choice #News

Myeloma
#CAR-T #Cell and gene therapy #Cell therapy #FDA #Myeloma #Poseida Therapeutics #Roche

‘Off-the-shelf’ CAR-T secures FDA advanced therapy designation

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Roche and Poseida Therapeutics’ P-BCMA-ALLO1. P-BCMA-ALLO1 is an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase I/Ib clinical development for the treatment of patients with relapsed/refractory multiple myeloma. The… Read More

#News #Regulatory

#Autoimmune disease #CAR-T #Cell therapy #FDA #Lupus #Synthekine

CAR-T and orthogonal IL-2 therapy for lupus fast-tracked by FDA

The US Food and Drug Administration (FDA) has granted fast track designation to SYNCAR-001 + STK-009. The treatment is indicated for patients with severe, refractory systemic lupus erythematosus (SLE), without the use of lymphodepletion. The fast-track designation follows investigational new drug (IND) clearance for a Phase I study evaluating SYNCAR-001… Read More

#News #Regulatory

CAR-T therapy
#CAR-T #Cell therapy #China #Legend Biotech #Myeloma #Oncology

Legend Biotech secures China cilta-cel approval for multiple myeloma

Legend Biotech (a subsidiary of GenScript Biotech) has received approval from the China National Medical Products Administration (NMPA) for cell therapy product, ciltacabtagene autoleucel (cilta-cel). The treatment is approved for use in adults with relapsed or refractory multiple myeloma (MM) who have undergone at least three prior lines of therapy,… Read More

#News #Regulatory

CAR-T cell therapy
#CAR-T #Cell and gene therapy #Cell therapy #Lymphoma #Oncology

The curative potential of CAR-T cell therapy

Dr Nicholas Siciliano, Co-Founder of Vittoria Biotherapeutics, shares insight on the VIPER-101 trial targeting T-cell lymphoma, the company’s aim to ensure progression free survival and opportunities in this sector.  MT: I understand that your lead programme is moving into the clinic, with POC human data expected in 2024. Can you… Read More

#Cancer Research #Exclusive Content

CAR-T therapy
#CAR-T #Caring Cross #Cell and gene therapy #Collaboration #GermFree #Manufacturing

Collaboration plans to democratise cell and gene therapies

Modular cleanroom company GermFree and non-profit Caring Cross have announced a new partnership, hoping to make cellular gene therapies more available to patients. The companies plan to create a decentralised, point-of-care manufacturing model that combines GermFree’s mobile cleanroom units with Caring Cross’s manufacturing technologies and pipeline… Read More

#News

CAR-T therapy
#Biosyngen #CAR-T #Cell therapy #FDA #Head and neck cancer #Oncology #Solid tumours

CAR-T therapy for nasopharyngeal cancer enters Phase II trials

The US Food and Drug Administration (FDA) has approved a Phase II clinical trial for Biosyngen’s BRG01, an EBV-specific CAR-T cell therapy. This marks the first cell therapy to enter Phase lI trials in both the US and China for the treatment of relapsed/metastatic EBV-positive nasopharyngeal carcinoma. The Center for… Read More

#News #Regulatory

#Advanced Therapies #Advanced Therapy Medicinal Products (ATMPs) #CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Guide #Market reporting

Podcast: The global innovation and the opportunity in CGTs

This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers five articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: The promise and growth of cell and gene therapies… Read More

#News

CAR-T therapy
#CAR-T #Cell therapy #FDA #Kyverna Therapeutics #Regenerative Medicine Advanced Therapy

Kyverna receives advanced therapy designation for KYV-101

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kyverna Therapeutic’s CAR-T candidate KYV-101 for refractory stiff-person syndrome (SPS). KYV-101 is an autologous, fully human CD19 CAR-T cell product candidate for use in B cell-driven autoimmune diseases. The RMAT designation was based on… Read More

#News #Regulatory

CAR-T cell therapy
#Autoimmune disease #CAR-T #Cell therapy #Lupus #Paediatrics #Universitätsklinikum Erlangen

Successful off-label use of CAR-T therapy in a child with lupus

In June 2023, a patient at Universitätsklinikum Erlangen in Germany became the first child with lupus to receive CAR-T therapy. The treatment was the last resort to slow down systemic lupus erythematosus (SLE), which is a serious autoimmune disease that was attacking the patient’s body and… Read More

#Editor's Choice #News